keyword
MENU ▼
Read by QxMD icon Read
search

cisplatin adriamycin

keyword
https://www.readbyqxmd.com/read/28713155/hypoxia-induces-universal-but-differential-drug-resistance-and-impairs-anticancer-mechanisms-of-5-fluorouracil-in-hepatoma-cells
#1
Jing-Qiu Li, Xian Wu, Lu Gan, Xiang-Liang Yang, Ze-Hong Miao
Hepatocellular carcinoma (HCC) is one of the most refractory cancers. The mechanisms by which hypoxia further aggravates therapeutic responses of advanced HCC to anticancer drugs remain to be clarified. Here, we report that hypoxia (1% O2) caused 2.55-489.7-fold resistance to 6 anticancer drugs (sorafenib, 5-fluorouracil [5-FU], gemcitabine, cisplatin, adriamycin and 6-thioguanine) in 3 HCC cell lines (BEL-7402, HepG2 and SMMC-7721). Among the 6 drugs, sorafenib, the sole one approved for HCC therapy, inhibited proliferation with little influence from hypoxia and displayed the smallest variation among the 3 HCC cell lines tested...
July 17, 2017: Acta Pharmacologica Sinica
https://www.readbyqxmd.com/read/28643750/evaluation-of-clinical-process-in-osteosarcoma-patients-treated-with-chemotherapy-including-cisplatin-adriamycin-ifosfamide-and-etoposide-and-determination-of-the-treatment-sequels-in-a-long-term-11-year-follow-up
#2
Mozaffar Aznab, Maryam Hematti
AIM: The aim of this study was to evaluate the effect of adding etoposide and ifosfamide chemotherapy drugs to treatment regimen of patients affected with osteosarcoma and to determine the clinical process and response to treatment during a follow-up period of 11 years. MATERIALS AND METHODS: Forty patients with osteosarcoma participated in this study from July 2005 to 2016. Treatments were started based on the following schema and after initial examinations including biochemical profile, checking for lung metastasis by simple radiography, chest computed tomography scan, and bones scan...
April 2017: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/28621239/a-microrna-signature-associated-with-pathological-complete-response-to-novel-neoadjuvant-therapy-regimen-in-triple-negative-breast-cancer
#3
Raúl García-Vazquez, Erika Ruiz-García, Abelardo Meneses García, Horacio Astudillo-de la Vega, Fernando Lara-Medina, Alberto Alvarado-Miranda, Héctor Maldonado-Martínez, Juan A González-Barrios, Alma D Campos-Parra, Sergio Rodríguez Cuevas, Laurence A Marchat, César López-Camarillo
Neoadjuvant chemotherapy aims to improve the outcome of breast cancer patients, but only few would benefit from this treatment. Pathological complete response has been proposed as a surrogate marker for the prediction of long-term clinical benefits; however, 50%-85% patients have an unfavorable pathological complete response to chemotherapy. MicroRNAs are known biomarkers of breast cancer progression; nevertheless, their potential to identify patients with pathological complete response remains poorly understood...
June 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/28588161/multimodality-treatment-outcome-of-hepatoblastoma-in-a-resource-limited-country
#4
M A Rahman, F Begum, S Karim, A Murtuza, A Islam
Our objective is to review the records of management of hepatoblastoma (HB) at the Paediatric Haematology and Oncology (PHO) department in the Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh from January 2004 to December 2012. This is a retrospective study of clinical, radiological and pathological data of hepatoblastoma patients treated at our institution. Thirteen patients were treated for HB between 2004 and 2012. The records of clinical presentations, chemotherapy tolerance and response, surgical procedure undertaken, and complications were analyzed...
April 2017: Mymensingh Medical Journal: MMJ
https://www.readbyqxmd.com/read/28532857/high-stathmin-expression-is-a-marker-for-poor-clinical-outcome-in-endometrial-cancer-an-nrg-oncology-group-gynecologic-oncology-group-study
#5
Henry D Reyes, Jeffrey Miecznikowski, Jesus Gonzalez-Bosquet, Eric J Devor, Yuping Zhang, Kristina W Thiel, Megan I Samuelson, Megan McDonald, Jean-Marie Stephan, Parviz Hanjani, Saketh Guntupalli, Krishnansu S Tewari, Floor Backes, Nilsa Ramirez, Gini F Fleming, Virginia Filiaci, Michael J Birrer, Kimberly K Leslie
OBJECTIVE: Gynecologic Oncology Group (GOG) 177 demonstrated that addition of paclitaxel to a backbone of adriamycin/cisplatin improves overall survival (OS) and progression-free survival (PFS) for patients with advanced or recurrent endometrial cancer. Using patient specimens from GOG-177, our objective was to identify potential mechanisms underlying the improved clinical response to taxanes. Stathmin (STMN1) is a recognized poor prognostic marker in endometrial cancer that functions as a microtubule depolymerizing protein, allowing cells to transit rapidly through mitosis...
May 19, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28432084/topoisomerase2%C3%AE-and-thymidylate-synthase-expression-in-adrenocortical-cancer
#6
Elisa Roca, Alfredo Berruti, Silviu Sbiera, Ida Rapa, Ester Oneda, Paola Sperone, Cristina L Ronchi, Laura Ferrari, Salvatore Grisanti, Antonina Germano, Barbara Zaggia, Giorgio Scagliotti, Martin Fassnacht, Marco Volante, Massimo Terzolo, Mauro Papotti
Topoisomerase II alpha (TOP2A) and Thymidylate Synthase (TS) are known prognostic parameters in several tumors and also predictors of efficacy of anthracyclines, topoisomerase inhibitors and fluoropirimidines, respectively. Expression of TOP2A and TS mRNA was assessed in 98 patients with adrenocortical carcinoma (ACC) and protein expression was assessed by immunohistochemistry in a subset of 39 tumors. Ninety-two patients were radically resected for stage II-III disease and 38 of them received adjuvant mitotane...
April 21, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28422743/efficacy-and-safety-of-dose-dense-chemotherapy-in-urothelial-carcinoma
#7
Chenjing Zhu, Jiaming Liu, Jing Zhang, Qingfang Li, Qisi Lian, Jing Xu, Xuelei Ma
We conducted a meta-analysis to assess the efficacy and safety of dose-dense chemotherapy in the treatment of patients with urothelial carcinoma. A systematic search was conducted in PubMed, Medline, Embase, Web of Science and Cochrane Collaboration's Central register of controlled trials (CENTRAL) for relevant articles. Data was obtained from 10 trials with a total of 1093 patients. The pooled pathologic complete response (pCR) was 27.8% in the ten studies with a full cohort of 684 patients who received dose-dense methotrexate, vinblastine, adriamycin and cisplatin (dd-MVAC)...
March 31, 2017: Oncotarget
https://www.readbyqxmd.com/read/28368679/calycosin-enhances-some-chemotherapeutic-drugs-inhibition-of-akt-signaling-pathway-in-gastric-cells
#8
Lixia Zhou, Yueming Wu, Yang Guo, Yanjun Li, Na Li, Yi Yang, Xueyun Qin
Although diagnosis and treatment of gastric cancer have improved, the prognosis of patients remains poor. The majority of patients should be treated with chemotherapy or other follow-up treatment. However, the drug resistance of chemotherapy and heterogeneity of tumor itself lead to differences of sensitivity of chemotherapy drugs for different patients. Therefore, it is mandatory to develop better methods of treatment for treatment of gastric cancer. Calycosin has been used in several types of cancer cells...
May 28, 2017: Cancer Investigation
https://www.readbyqxmd.com/read/28367234/differentiation-by-nk-cells-is-a-prerequisite-for-effective-targeting-of-cancer-stem-cells-poorly-differentiated-tumors-by-chemopreventive-and-chemotherapeutic-drugs
#9
Anna Karolina Kozlowska, Paytsar Topchyan, Kawaljit Kaur, Han-Ching Tseng, Antonia Teruel, Toru Hiraga, Anahid Jewett
Natural Killer (NK) cells target oral, pancreatic, lung, breast, glioblastoma and melanoma stem-like/poorly differentiated tumors. Differentiation of the abovementioned tumors with supernatants from split-anergized NK cells decreases their susceptibility to NK cells, but increases their sensitivity to cisplatin (CDDP)-mediated cell death. Breast and melanoma tumor cells with CD44 knockdown display enhanced susceptibility to NK cell-mediated lysis, potentially due to decreased differentiation. We also demonstrate that sulindac, a non-steroidal anti-inflammatory drug and a chemopreventive agent, not only limits the growth of oral tumor cells, but also aids in cancer cell elimination by NK cells...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28356114/effectiveness-of-multi-drug-regimen-chemotherapy-treatment-in-osteosarcoma-patients-a-network-meta-analysis-of-randomized-controlled-trials
#10
Xiaojie Wang, Hong Zheng, Tao Shou, Chunming Tang, Kun Miao, Ping Wang
BACKGROUND: Osteosarcoma is the most common malignant bone tumour. Due to the high metastasis rate and drug resistance of this disease, multi-drug regimens are necessary to control tumour cells at various stages of the cell cycle, eliminate local or distant micrometastases, and reduce the emergence of drug-resistant cells. Many adjuvant chemotherapy protocols have shown different efficacies and controversial results. Therefore, we classified the types of drugs used for adjuvant chemotherapy and evaluated the differences between single- and multi-drug chemotherapy regimens using network meta-analysis...
March 29, 2017: Journal of Orthopaedic Surgery and Research
https://www.readbyqxmd.com/read/28347917/induction-of-apoptotic-dna-fragmentation-mediated-by-mitochondrial-pathway-with-caspase-3-dependent-bid-cleavage-in-human-gastric-cancer-cells-by-a-new-nitroxyl-spin-labeled-derivative-of-podophyllotoxin
#11
Yu-Jie Yang, She-Ning Qi, Rui-Yue Shi, Jun Yao, Li-Sheng Wang, Hu-Qin Yuan, Yuan-Xue Jing
PURPOSE: 4-[4''-(2'', 2'', 6'', 6''-tetramethyl-l''-piperidinyloxy) amino]-4'-demethyl-epipodophyllotoxin (GP7) is a new semi-synthesized nitroxyl spin-labeled derivative of podophyllotoxin with anti-leukemic and anti-osteosarcoma effects. The purpose of the present study is to investigate the anti-gastric cancer (GC) effects of GP7 and the possible involvement of caspase pathway in GP7-induced apoptotic DNA fragmentation in human GC cells. MATERIALS AND METHODS: Effects of GP7 on the proliferation of human GC cell lines MKN28, AGS, BGC-823 and HGC-27 in different degrees of differentiation and normal human gastric epithelial cell line GES-1 were studied by MTT assay and compared with the effects of etoposide...
June 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/28272005/bilateral-breast-cancer-after-prophylactic-bilateral-pulmonary-irradiation
#12
Hamrouni A El Meddeb, Jebsi M Chehata, S Kanoun, C Rancoule, J B Guy, N Magne, N Bouaouina
The purpose of this article is to report a new case of a probably radio-induced bilateral breast cancer occurred after prophylactic bilateral pulmonary irradiation in the treatment of osteosarcoma. A 42-year-old woman, treated at the age of 12 years for osteosarcoma at the right lower limb with chemotherapy (methotrexate, adriamycin and cisplatin) followed by non-conservative surgery and adjuvant radiotherapy. Eighteen years after, she developed her first breast cancer, and five years later, her second contralateral breast cancer...
January 2017: Gulf Journal of Oncology
https://www.readbyqxmd.com/read/28260105/depletion-of-tfap2e-attenuates-adriamycin-mediated-apoptosis-in-human-neuroblastoma-cells
#13
Reina Hoshi, Yosuke Watanabe, Yoshiaki Ishizuka, Takayuki Hirano, Eri Nagasaki-Maeoka, Shinsuke Yoshizawa, Shota Uekusa, Hiroyuki Kawashima, Kensuke Ohashi, Kiminobu Sugito, Noboru Fukuda, Hiroki Nagase, Masayoshi Soma, Toshinori Ozaki, Tsugumichi Koshinaga, Kyoko Fujiwara
Neuroblastoma is a childhood malignancy originating from the sympathetic nervous system and accounts for approximately 15% of all pediatric cancer-related deaths. To newly identify gene(s) implicated in the progression of neuroblastoma, we investigated aberrantly methylated genomic regions in mouse skin tumors. Previously, we reported that TFAP2E, a member of activator protein-2 transcription factor family, is highly methylated within its intron and its expression is strongly suppressed in mouse skin tumors compared with the normal skin...
April 2017: Oncology Reports
https://www.readbyqxmd.com/read/28260018/effects-of-5-fluorouracil-adriamycin-and-irinotecan-on-hsc-39-a-human-scirrhous-gastric-cancer-cell-line
#14
Rie Tamaki, Aya Kanai-Mori, Yuta Morishige, Atsushi Koike, Kazuyoshi Yanagihara, Fumio Amano
Therapies for patients with scirrhous gastric cancer remain ineffective. Current treatments for gastric cancer based on systemic therapy, such as the combination of S-1 with cisplatin or docetaxel, show good clinical response rates. S-1 plus cisplatin is the standard treatment for HER2-negative advanced scirrhous gastric cancer in Japan. In spite of recent advances in the treatment of gastric cancer, a standard chemotherapy regimen is yet to be established for scirrhous gastric cancer. To develop new therapeutic approaches based on characteristic biological features of cancer cells, we examined the mechanisms underlying the cytotoxicity of anticancer drugs and reactive oxygen species (ROS) toward a human scirrhous cancer cell line, HSC-39, in vitro...
April 2017: Oncology Reports
https://www.readbyqxmd.com/read/28177244/replacing-d-glucosamine-with-its-l-enantiomer-in-glycosylated-antitumor-ether-lipids-gaels-retains-cytotoxic-effects-against-epithelial-cancer-cells-and-cancer-stem-cells
#15
Makanjuola Ogunsina, Pranati Samadder, Temilolu Idowu, Gilbert Arthur, Frank Schweizer
We describe metabolically inert l-glucosamine-based glycosylated antitumor ether lipids (L-GAELs) that retain the cytotoxic effects of the D-GAELs including the ability to kill BT-474 breast cancer stem cells (CSCs). When compared to adriamycin, cisplatin, and the anti-CSC agent salinomycin, L-GAELs display superior activity to kill cancer stem cells (CSCs). Mode of action studies indicate that L-GAELs like the D-GAELs kill cells via an apoptosis-independent mechanism that was not due to membranolytic effects...
February 21, 2017: Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/28117134/palliative-chemotherapy-for-bladder-cancer-treatment-delivery-and-outcomes-in-the-general-population
#16
Andrew G Robinson, Xuejiao Wei, Francisco E Vera-Badillo, William J Mackillop, Christopher M Booth
BACKGROUND: Palliative chemotherapy for advanced bladder cancer is recommended in clinical practice guidelines because of the results achieved in clinical trials. However, real-world treatment and outcomes have not been well described. We report the treatment delivery and survival associated with palliative chemotherapy in routine clinical practice. MATERIALS AND METHODS: The population-based Ontario Cancer Registry was linked to electronic records of treatment to identify all patients with bladder cancer treated with palliative chemotherapy in Ontario during 1994 to 2008...
December 29, 2016: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28099947/short-term-efficacy-of-different-chemotherapy-regimens-in-the-treatment-of-advanced-gastric-cancer-a-network-meta-analysis
#17
Mi-Ma Duo-Ji, Ba-Sang Ci-Ren, Zi-Wen Long, Xiao-Hua Zhang, Dong-Lin Luo
OBJECTIVE: A network meta-analysis was performed to compare the short-term efficacy of different chemotherapy regimens in the treatment of advanced gastric cancer. METHODS: Randomized controlled trials of different chemotherapy regimens for advanced gastric cancer were included in this study. Network meta-analysis combined direct evidence and indirect evidence to evaluate the odds ratio and draw surface under the cumulative ranking curves of different chemotherapy regimens in advanced gastric cancer...
June 6, 2017: Oncotarget
https://www.readbyqxmd.com/read/28097015/co-administration-of-dexamethasone-increases-severity-and-accelerates-onset-day-of-neutropenia-in-bladder-cancer-patients-on-methotrexate-vinblastine-adriamycin-and-cisplatin-chemotherapy-a-retrospective-cohort-study
#18
Shingo Itai, Yukio Suga, Yusuke Hara, Kouji Izumi, Yuji Maeda, Yasuhide Kitagawa, Junko Ishizaki, Tsutomu Shimada, Atsushi Mizokami, Yoshimichi Sai
BACKGROUND: Bladder cancer patients receiving methotrexate, vinblastine, adriamycin and cisplatin (MVAC) chemotherapy are co-administered with dexamethasone as an anti-emetic. We examined whether or not dexamethasone affects the severity and onset day of MVAC-induced severe neutropenia. METHODS: This was a retrospective study of bladder cancer patients treated with MVAC chemotherapy with or without dexamethasone as an antiemetic at Kanazawa University Hospital during January 2005 - December 2009...
2017: Journal of Pharmaceutical Health Care and Sciences
https://www.readbyqxmd.com/read/28052947/primitive-neuroectodermal-tumour-of-the-cervix-a-rare-diagnosis
#19
Irfan Ahmad, Kundan Singh Chufal, Amit Bhargava, Irfan Bashir
A 48-year-old woman presented with symptoms of lower abdominal pain and vaginal discharge for 6 months. Clinical examination and pelvic ultrasound scan suggested a diagnosis of infected Gartner's cyst, for which she underwent vaginal cystectomy. However, histopathology and immunohistochemistry revealed a diagnosis of primitive neuroectodermal tumour of the cervix. Further investigations revealed the stage to be FIGO IIIB, which was inoperable. She received neoadjuvant chemotherapy (vincristine, adriamycin, cyclophosphamide alternating with ifosfamide, cisplatin and etoposide, every 21 days), but the tumour did not respond to treatment and she was started on radiotherapy with definitive intent (55...
January 4, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/27907921/feasibility-of-preoperative-chemotherapy-with-docetaxel-cisplatin-and-5-fluorouracil-versus-adriamycin-cisplatin-and-5-fluorouracil-for-resectable-advanced-esophageal-cancer
#20
Osamu Shiraishi, Makoto Yamasaki, Tomoki Makino, Masaaki Motoori, Hiroshi Miyata, Masayuki Shinkai, Yutaka Kimura, Motohiro Hirao, Kazumasa Fujitani, Shigeyuki Tamura, Kenji Kobayashi, Masahiko Yano, Yuichiro Doki, Takushi Yasuda
BACKGROUND: Neoadjuvant chemotherapy for resectable advanced esophageal squamous cell carcinoma (ESCC) requires reassessment. We have conducted a trial aiming at the comparison between DCF and ACF concerning perioperative adverse events. METHODS: Patients were randomly assigned to receive either DCF [docetaxel 70 mg/m2, cisplatin 70 mg/m2 on day 1, and 5-fluorouracil (5-FU) 700 mg/m2 for 5 days] every 3 weeks or ACF (adriamycin 35 mg/m2, cisplatin 70 mg/m2 on day 1, and 5-FU 700 mg/m2 for 7 days) every 4 weeks...
2017: Oncology
keyword
keyword
22454
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"